Unmet need in Chinese market

The market size of the product in China is expected to reach 6.5 billion RMB in 2023 and exceed 10 billion RMB by 2030.

indications:

• Colorectal cancer
• Non-small cell lung cancer
• Glioblastoma
• Cervical cancer
• Epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Exclusive commercialization
collaboration in mainland China

Exclusive commercialization
authorization for overseas markets

• Glioblastoma multiform or mesenchymal astrocytoma relapsed or progressed after conventional oncology therapies
• Newly diagnosed glioblastoma multiform, for which Tazian® can be initially used in combination with radiotherapy, then can be used as maintenance therapy

We have promoted commercial sales of the products together with Jemincare through CSO cooperation with Jemincare.

Accurately locate patient groups and segment market promotion channels

• Anorexia in patients with acquired immunodeficiency syndrome
• Significant weight loss due to cachexia in patients with acquired immunodeficiency syndrome or cancer

TOT BIOPHARM has promoted the commercial product sales inoncology field through the joint venture Hua Yao, and in the field of AIDS therapy through CSO collaboration with FRONTIER BIOTECHNOLOGIES Inc.